The Role of Mitochondria in Statin-Induced Myopathy.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic pathways with no systematic review or new primary human data.
PubMed 38492173 · doi:10.1007/s40264-024-01413-9
What was done
This narrative review synthesized the available literature on mechanisms linking statin therapy to mitochondrial dysfunction and statin-induced myopathy, focusing on CoQ10 biosynthesis inhibition, impaired Ca2+ signaling, and altered reactive oxygen species generation.
What was found
The abstract reports no numerical findings, effect sizes, or study counts. It describes qualitative mechanistic pathways contributing to muscle complaints (pain, weakness, fatigue) and elevated creatine kinase in statin-treated patients.
Why it matters
Understanding the cellular and mitochondrial mechanisms of statin-induced muscle symptoms can help inform future targeted therapies or prevention strategies for affected patients requiring lipid-lowering treatment.
Limits
This is a narrative review without systematic search methodology, meta-analytic data, or new human clinical trials. The abstract provides no quantitative data, sample sizes, or patient cohort details.
Cited by
- supports Statins deplete the electron transport chain and cause coenzyme Q10 deficiency.